<DOC>
	<DOC>NCT00357188</DOC>
	<brief_summary>The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects</brief_summary>
	<brief_title>Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>BMI 1830 Men and women who are not of childbearing potential, ages 1850 years, inclusive History of seizures or other central nervous system disorders (including migraine headaches) history of diagnosed mental illness or suicidal tendencies positive screening for Hep B surface antigen Hep C antibody HIV1, 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>